[
  {
    "ts": null,
    "headline": "West Pharmaceutical Services to Buy Back Up To 550,000 Shares",
    "summary": "West Pharmaceutical Services to Buy Back Up To 550,000 Shares",
    "url": "https://finnhub.io/api/news?id=44fd4bff6e6295c4f695c4bb8bf68cc4457756878472b94c848c43c2245f5968",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734106980,
      "headline": "West Pharmaceutical Services to Buy Back Up To 550,000 Shares",
      "id": 132157999,
      "image": "",
      "related": "WST",
      "source": "MarketWatch",
      "summary": "West Pharmaceutical Services to Buy Back Up To 550,000 Shares",
      "url": "https://finnhub.io/api/news?id=44fd4bff6e6295c4f695c4bb8bf68cc4457756878472b94c848c43c2245f5968"
    }
  },
  {
    "ts": null,
    "headline": "West Pharmaceutical upgraded to Buy from Neutral at UBS",
    "summary": "UBS upgraded West Pharmaceutical (WST) to Buy from Neutral with a price target of $390, up from $350. The firm has incremental confidence in a positive mix shift driven by Annex 1 regulations, wearable injectors, and GLP-1 tailwinds, and tells investors in a research that coupled with a view that destocking headwinds should dissipate soon, the combination drives confidence West can return to long- range plan growth earlier than expected, driving stock performance. Published first on TheFly – the",
    "url": "https://finnhub.io/api/news?id=0cfe57bb984e105c342ec0bcc07e33f73c2652bc64c065de1fe1ae2a7aae8e41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734094842,
      "headline": "West Pharmaceutical upgraded to Buy from Neutral at UBS",
      "id": 131969727,
      "image": "https://media.zenfs.com/en/tipranks_452/c37c6416e3d93ec36371ae85ba3ad4a9",
      "related": "WST",
      "source": "Yahoo",
      "summary": "UBS upgraded West Pharmaceutical (WST) to Buy from Neutral with a price target of $390, up from $350. The firm has incremental confidence in a positive mix shift driven by Annex 1 regulations, wearable injectors, and GLP-1 tailwinds, and tells investors in a research that coupled with a view that destocking headwinds should dissipate soon, the combination drives confidence West can return to long- range plan growth earlier than expected, driving stock performance. Published first on TheFly – the",
      "url": "https://finnhub.io/api/news?id=0cfe57bb984e105c342ec0bcc07e33f73c2652bc64c065de1fe1ae2a7aae8e41"
    }
  },
  {
    "ts": null,
    "headline": "UBS Upgrades West Pharmaceutical Services (WST)",
    "summary": "UBS Upgrades West Pharmaceutical Services (WST)",
    "url": "https://finnhub.io/api/news?id=7a1ceb6b266e5d28c2b80403b2b774b61b3afa4b822e16ff8a22c1e376ea0dc0",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734048329,
      "headline": "UBS Upgrades West Pharmaceutical Services (WST)",
      "id": 131955467,
      "image": "",
      "related": "WST",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=7a1ceb6b266e5d28c2b80403b2b774b61b3afa4b822e16ff8a22c1e376ea0dc0"
    }
  }
]